<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="28379"><DrugName>Glutoxim</DrugName><DrugNamesKey><Name id="42828411">Glutoxim</Name></DrugNamesKey><DrugSynonyms><Name><Value>BAM-002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Glutoxim</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>NOV-002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Glutoxim + cisplatin</Value></Name><Name><Value>15663-27-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>103239-24-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>27025-41-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1015614">Pharma Vam</CompanyOriginator><CompaniesPrimary><Company id="1015614">Pharma Vam</Company><Company id="27692">Cellectar Biosciences Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1023179">Lee's Pharmaceutical Holdings Limited</Company><Company id="1045514">Mundipharma International Corp Ltd</Company><Company id="23066">Phytera Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28379" type="Drug"><TargetEntity id="289126" type="siDrug">Glutathione disulfide</TargetEntity></SourceEntity><SourceEntity id="1015614" type="Company"><TargetEntity id="5035524792" type="organizationId">Farma Vam ZAO</TargetEntity></SourceEntity><SourceEntity id="1023179" type="Company"><TargetEntity id="4295871517" type="organizationId">Lee's Pharmaceutical Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="1045514" type="Company"><TargetEntity id="5035938515" type="organizationId">Mundipharma International Corp Ltd</TargetEntity></SourceEntity><SourceEntity id="23066" type="Company"><TargetEntity id="4296392127" type="organizationId">Phytera Inc</TargetEntity></SourceEntity><SourceEntity id="27692" type="Company"><TargetEntity id="4295899690" type="organizationId">Cellectar Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="154" type="ciIndication"><TargetEntity id="10019717" type="MEDDRA"/><TargetEntity id="D006505" type="MeSH"/><TargetEntity id="-1968993298" type="omicsDisease"/><TargetEntity id="424" type="siCondition"/></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="367" type="ciIndication"><TargetEntity id="10063155" type="MEDDRA"/><TargetEntity id="D054508" type="MeSH"/><TargetEntity id="-1541096986" type="omicsDisease"/><TargetEntity id="1818" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"/><TargetEntity id="10062042" type="MEDDRA"/><TargetEntity id="D008175" type="MeSH"/><TargetEntity id="-243902424" type="omicsDisease"/><TargetEntity id="611" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Lung tumor - Russian Federation - Apr-2000</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="367">Radiation sickness</Indication><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication><Indication id="755">Lung tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="154">Hepatitis</Indication><Indication id="281">Psoriasis</Indication></IndicationsSecondary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action><Action id="825">Glutathione modulator</Action><Action id="1276">Chemoprotectant</Action><Action id="1465">Radioprotectant</Action><Action id="15184">Systemic antipsoriatic product</Action><Action id="1545">Anticancer</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="651">Intramuscular formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-19T13:26:11.000Z</LastModificationDate><ChangeDateLast>2018-09-18T00:00:00.000Z</ChangeDateLast><AddedDate>2000-04-20T15:11:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1015614" linkType="Company"&gt;Pharma Vam&lt;/ulink&gt; (PharmaBAM) developed and launched Glutoxim for lung cancer. NOV-002 was approved for use in Russia in September 1998 [&lt;ulink linkID="363605" linkType="Reference"&gt;363605&lt;/ulink&gt;], where it is marketed as Glutoxim by &lt;ulink linkID="1015614" linkType="Company"&gt;Pharma Vam&lt;/ulink&gt; (PharmaBAM) for lung cancer [&lt;ulink linkID="607922" linkType="Reference"&gt;607922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27692" linkType="Company"&gt;Cellectar Biosciences&lt;/ulink&gt;  (formerly Novelos Therapeutics), Chinese developer &lt;ulink linkID="1023179" linkType="Company"&gt;Lee's Pharmaceuticals&lt;/ulink&gt;, and licensee &lt;ulink linkID="1045514" linkType="Company"&gt;Mundipharma International&lt;/ulink&gt;, were previously developing NOV-002 (BAM-002, Glutoxim, structure shown),  a glutathione disulfide mimetic form of an endogenous peptide, for the potential injectable treatment of ovarian cancer, breast cancer, and as a radiation protectant [&lt;ulink linkID="363605" linkType="Reference"&gt;363605&lt;/ulink&gt;]. In July 2006, a phase II trial of the drug in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; began in patients with ovarian tumors [&lt;ulink linkID="678919" linkType="Reference"&gt;678919&lt;/ulink&gt;]. By April 2007, a phase II trial for early-stage breast cancer had begun [&lt;ulink linkID="783763" linkType="Reference"&gt;783763&lt;/ulink&gt;]; in July 2010,  the company was planning  on designing a larger, randomized,  controlled trial for breast cancer and  to initiate    development of the drug for other solid tumors in combination with immunogenic chemotherapies [&lt;ulink linkID="1117946" linkType="Reference"&gt;1117946&lt;/ulink&gt;]. In May 2007, the drug was accepted into the NIH/NIAID's radiation/nuclear medical countermeasures product development program [&lt;ulink linkID="797140" linkType="Reference"&gt;797140&lt;/ulink&gt;]. However, by April  2011,  Cellectar Biosciences had suspended   development           [&lt;ulink linkID="2071133" linkType="Reference"&gt;2071133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novelos was previously developing NOV-002 for the potential treatment of non-small-cell lung cancer (NSCLC) [&lt;ulink linkID="363605" linkType="Reference"&gt;363605&lt;/ulink&gt;]. In May 2006, Novelos agreed an SPA with the FDA for a phase III trial in advanced NSCLC [&lt;ulink linkID="670009" linkType="Reference"&gt;670009&lt;/ulink&gt;]. In January 2010, the company planned to file an NDA for NSCLC in the third quarter of 2010 [&lt;ulink linkID="1067158" linkType="Reference"&gt;1067158&lt;/ulink&gt;]. However, in February 2010, it was reported that the primary survival endpoint had not been met in the phase III trial [&lt;ulink linkID="1077155" linkType="Reference"&gt;1077155&lt;/ulink&gt;]; in March 2010, Novelos discontinued development of the drug for NSCLC [&lt;ulink linkID="1083115" linkType="Reference"&gt;1083115&lt;/ulink&gt;]. In June 2010, Pharma Vam reported that the version of the drug used in the study, which had been produced using a modified manufacturing process, differed from those used in previous studies [&lt;ulink linkID="1111451" linkType="Reference"&gt;1111451&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Novelos was previously developing the drug for psoriasis and hepatitis [&lt;ulink linkID="363605" linkType="Reference"&gt;363605&lt;/ulink&gt;]. By August 2005, Russian clinical studies in psoriasis and viral hepatitis had been conducted [&lt;ulink linkID="617143" linkType="Reference"&gt;617143&lt;/ulink&gt;]. However, no development for has since been reported and the program is presumed to be discontinued for these indications.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="23066" linkType="Company"&gt;Phytera&lt;/ulink&gt; was previously developing  NOV-002. In April 2000, Phytera obtained exclusive North American rights to NOV-002 in the US. The alliance provided Novelos with a North American commercialization partner [&lt;ulink linkID="378896" linkType="reference"&gt;378896&lt;/ulink&gt;]; however, as the company appeared to have gone out of business, its involvement in this program is assumed to have been discontinued.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In June 2005, Novelos filed for US Orphan Drug status for the treatment of refractory ovarian cancer with NOV-002 in combination with chemotherapy. The company expected a response from the FDA in mid-August 2005 [&lt;ulink linkID="607922" linkType="Reference"&gt;607922&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2006, the FDA granted Fast Track status to NOV-002 for use in combination with first-line chemotherapy for the treatment of NSCLC [&lt;ulink linkID="682452" linkType="Reference"&gt;682452&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;NSCLC&lt;/subtitle&gt;In December 2005, the FDA agreed that a phase III study of NOV-002 in combination with first-line chemotherapy for NSCLC was warranted. During an end-of-phase II meeting, the agency agreed that a single controlled study would be sufficient to support approval of NOV-002 for the first-line treatment of chemotherapy-naive stage IIIb/IV NSCLC patients. Novelos would seek to finalize the phase III study design under an SPA during the first half of 2006. The primary endpoint of the trial, which was expected to begin in the third quarter of 2006, would be overall survival [&lt;ulink linkID="638813" linkType="Reference"&gt;638813&lt;/ulink&gt;]. In March 2006, the company filed an SPA with the FDA [&lt;ulink linkID="654448" linkType="Reference"&gt;654448&lt;/ulink&gt;] and in May 2006 the parties finalized the SPA. The international, randomized, open-label trial would compare NOV-002 plus &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and carboplatin to paclitaxel and carboplatin alone in 840 patients with stage IIIb/IV disease; enrollment was scheduled to begin in the third quarter of 2006 [&lt;ulink linkID="670009" linkType="Reference"&gt;670009&lt;/ulink&gt;]. In June 2006, a randomized, open-label, controlled phase III trial began to assess the efficacy of NOV-002 in combination with paclitaxel plus carboplatin, compared with paclitaxel plus carboplatin alone, in NSCLC patients (expected enrollment n = 840) with advanced NSCLC. The primary endpoint was to be overall survival when compared with paclitaxel plus carboplatin alone. Secondary endpoints were to include progression free survival, tumor response rate and duration of response, quality of life, myelosuppression and immunomodulation [&lt;ulink linkID="683756" linkType="Reference"&gt;683756&lt;/ulink&gt;]. Enrollment began in November 2006 and the company expected to complete recruitment in the first quarter of 2008 [&lt;ulink linkID="739771" linkType="Reference"&gt;739771&lt;/ulink&gt;]. In March 2008, Novelos reported it had completed enrollment of 840 patients with stage IIIb/IV NSCLC. It was also reported that an independent data monitoring committee had recommended the trial continue unmodified after each quarterly data review. At that time, the trial was expected to conclude following the occurrence of 725 events and topline data were expected in mid-2009 [&lt;ulink linkID="885652" linkType="Reference"&gt;885652&lt;/ulink&gt;]. In February 2009, the trial was expected to conclude in late 2009 [&lt;ulink linkID="983528" linkType="Reference"&gt;983528&lt;/ulink&gt;]. In August 2009, the trial was expected to finish in early 2010 [&lt;ulink linkID="1036432" linkType="Reference"&gt;1036432&lt;/ulink&gt;]. In January 2010, the 725th patient death occurred, triggering a prespecified analysis of the data. Topline results were expected later in the first quarter of 2010. At that time, 903 patients had been enrolled in the trial [&lt;ulink linkID="1067158" linkType="Reference"&gt;1067158&lt;/ulink&gt;]. In February 2010, it was reported that the trial had failed to meet its primary endpoint of improvement in overall survival. Survival in the control arm exceeded expectations, which were based on historical data [&lt;ulink linkID="1077155" linkType="Reference"&gt;1077155&lt;/ulink&gt;]. In March 2010, detailed data from the trial were to be presented in June 2010, at the annual meeting of the American Society of Clinical Oncology in Chicago, IL [&lt;ulink linkID="1083115" linkType="Reference"&gt;1083115&lt;/ulink&gt;]. In June 2010, Pharma Vam tested samples of the drug used in Novelos' phase III study. Tests showed the version of the drug used in the study, which had been produced using a modified manufacturing process, differed from those used in previous studies [&lt;ulink linkID="1111451" linkType="Reference"&gt;1111451&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By January 2010, results from a Russian, phase II trial evaluating NOV-002 in combination with cisplatin-based first-line chemotherapy, showed NOV-002 increased the 1-year survival rate from 17 to 63%. At 14 months, median survival was not reached in NOV-002-treated patients compared with a median survival of 7 months in the active control [&lt;ulink linkID="1067158" linkType="Reference"&gt;1067158&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2005, Novelos was to meet with the FDA in December 2005 to discuss results from its phase I/II trial of NOV-002 in NSCLC and to present its design for a phase III study of the drug, which it hoped to conduct under a SPA [&lt;ulink linkID="630211" linkType="Reference"&gt;630211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, Novelos began an open-label, controlled, US  phase I/II study  in 84 patients, who would be randomized to one of three arms  (chemotherapy alone; chemotherapy plus iv and im NOV-002; chemotherapy plus iv and sc NOV-002). The study endpoints included tumor response, 1-year survival and hematopoeitic recovery following chemotherapy [&lt;ulink linkID="363605" linkType="reference"&gt;363605&lt;/ulink&gt;]. Recruitment was ongoing in November 2000 [&lt;ulink linkID="390015" linkType="Reference"&gt;390015&lt;/ulink&gt;] and completion of the trial was expected by 2002 [&lt;ulink linkID="426698" linkType="Reference"&gt;426698&lt;/ulink&gt;]. It had been completed by June 2005 [&lt;ulink linkID="607922" linkType="Reference"&gt;607922&lt;/ulink&gt;]. In August 2005, the company reported results that showed NOV-002 was better tolerated and improved objective tumor response to a greater extent than placebo. The trial had tested the drug in 44 late-stage NSCLC patients who were chemotherapy-naive.  In the group which received the drug iv and sc, 69% experienced tumor shrinkage by at least half, compared to only 33% in the control group. In the group of patients which received iv and sc NOV-002 plus chemotherapy, 46% demonstrated an objective response. Those on NOV-002 were able to receive more cycles of chemotherapy than those on chemotherapy alone, and the drug was well tolerated [&lt;ulink linkID="616701" linkType="Reference"&gt;616701&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;In July 2006,  a US phase II study of NOV-002 in combination with carboplatin began in platinum-resistant ovarian cancer patients. The open-label, single-arm study would determine  tumor response rate in 25 women, following up to six cycles of NOV-002.  Interim results were expected in early 2007 [&lt;ulink linkID="678919" linkType="Reference"&gt;678919&lt;/ulink&gt;], [&lt;ulink linkID="683753" linkType="Reference"&gt;683753&lt;/ulink&gt;]. Preliminary data from the trial were reported in June 2007. Of 10 patients, one had a partial response, five had stable disease and four had progressive disease. The drug was well tolerated [&lt;ulink linkID="805688" linkType="Reference"&gt;805688&lt;/ulink&gt;]. In March 2008, further data from the trial were reported. Of 15 evaluable patients, 9 (60%) had slower than expected disease progression. At that time, a second phase II trial in platinum-resistant ovarian cancer  was expected to begin in early 2009 [&lt;ulink linkID="891621" linkType="Reference"&gt;891621&lt;/ulink&gt;]. By November 2009, phase II development was ongoing [&lt;ulink linkID="1058830" linkType="Reference"&gt;1058830&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In Russian clinical studies conducted prior to June 2005, NOV-002 sensitized resistant ovarian tumors, which raised the patient response rate to chemotherapy [&lt;ulink linkID="607922" linkType="Reference"&gt;607922&lt;/ulink&gt;], [&lt;ulink linkID="617143" linkType="Reference"&gt;617143&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In July 2010,  the company was planning  on designing a larger, randomized,  controlled trial for breast cancer [&lt;ulink linkID="1117946" linkType="Reference"&gt;1117946&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2007, Novelos began enrollment in a US phase II trial of NOV-002 in combination with chemotherapy for early-stage breast cancer. Interim results were expected in mid-2008. The open-label, single-arm trial would assess rate of pathologic complete response (pCR) after preoperative administration of NOV-002 in combination with doxorubicin and &lt;ulink linkID="52332" linkType="Drug"&gt;cyclophosphamide&lt;/ulink&gt; followed by &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in 46 patients with stage IIB/IIIC HER-2/neu negative disease. Subjects would receive up to eight cycles of therapy [&lt;ulink linkID="802219" linkType="Reference"&gt;802219&lt;/ulink&gt;]. Interim data were reported in May 2008. Of the 16 currently enrolled patients, four pCRs were seen in eight patients that had completed chemotherapy, which met the trial's criteria to enroll a further 30 patients. The drug also decreased hematologic toxicities and the use of growth factors. At that time, full enrollment was expected to be completed in mid-2009 and the study was scheduled to end in early 2010 [&lt;ulink linkID="904470" linkType="Reference"&gt;904470&lt;/ulink&gt;]. Further data were reported in December 2008 at the AACR Breast Cancer Symposium in San Antonio, TX. By that time, 19 patients had been enrolled and the company planned to complete enrollment in the third quarter of 2009. In the first 15 patients who had completed chemotherapy and undergone surgery,  6 pCRs had been observed [&lt;ulink linkID="970613" linkType="Reference"&gt;970613&lt;/ulink&gt;]. In November 2009, phase II development was still ongoing [&lt;ulink linkID="1058830" linkType="Reference"&gt;1058830&lt;/ulink&gt;]. In February 2010, further results were expected in the third quarter of 2010 [&lt;ulink linkID="1077155" linkType="Reference"&gt;1077155&lt;/ulink&gt;]. In July 2010, it was reported that 39 patients had been enrolled, and that of 31 patients who had undergone surgery, 12 had confirmed pCRs. At that time, enrollment was continuing [&lt;ulink linkID="1115545" linkType="Reference"&gt;1115545&lt;/ulink&gt;]. In December 2010, further data were presented at the AACR Breast Cancer Symposium in San Antonio, TX. By that time, 15 pCRs had been achieved in the 38 patients who had had surgery [&lt;ulink linkID="1155210" linkType="Reference"&gt;1155210&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2007, a phase II trial for early-stage breast cancer was ongoing [&lt;ulink linkID="783763" linkType="Reference"&gt;783763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other indications&lt;/subtitle&gt;By August 2005, NOV-002 had also shown efficacy in Russian clinical studies in psoriasis and viral hepatitis [&lt;ulink linkID="617143" linkType="Reference"&gt;617143&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Clinical studies conducted prior to April 2000 in more than 2000 patients with various cancers in Russia, Italy and the Ivory Coast demonstrated that NOV-002 was safe, well tolerated and had a high degree of efficacy. In a controlled clinical trial undertaken in Russia in 68 patients with Stage III and IV NSCLC, 64% of patients receiving NOV-002 with chemotherapy (&lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt;-based) survived for more than 1 year compared to 15% of patients receiving chemotherapy alone [&lt;ulink linkID="363605" linkType="reference"&gt;363605&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. In the CT26 murine colon cancer model, NOV-002 plus cyclophosphamide inhibited tumor development  via a transferrable, immune-based mechanism, and administration of NOV-002 to mice resulted in  S-glutathionylation of Serpin-A1 and A3 in the plasma, implying a link between modulation of Serpin activity and the  myeloproliferative actions of NOV-002. In human tumor and myeloid cell lines, NOV-002 induced  oxidative signaling, protein modification (S-glutathionylation) and cell signalling changes, with an anti-proliferative/apoptotic outcome in  tumor cells contrasting with a proliferative stimulus in  myeloid cells [&lt;ulink linkID="1091694" linkType="Reference"&gt;1091694&lt;/ulink&gt;], [&lt;ulink linkID="1090156" linkType="Reference"&gt;1090156&lt;/ulink&gt;] [&lt;ulink linkID="1088201" linkType="Reference"&gt;1088201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, preclinical data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. In melanoma mice models, daily injections of NOV-002 (25 mg/kg intraperitoneally) for 7 days significantly delayed tumor progression and increased overall survival [&lt;ulink linkID="1058830" linkType="Reference"&gt;1058830&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009,  Novelos and &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; (MGH) were awarded funding to study NOV-002 for the mitigation and treatment of radiation-induced pulmonary injury in animal models [&lt;ulink linkID="1045646" linkType="Reference"&gt;1045646&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the American Association for Cancer Research Tumor Immunology conference in Miami, FL. NOV-002 reversed the suppression of tumor antigen-specific T-cell activation by cyclophosphamide-induced myeloid derived suppressor cells in mice. In a murine model of ovarian cancer, NOV-002 increased infiltration of memory T-cells into the tumor; splenocytes from these mice also demonstrated a higher level of immune reactivity (higher IFN-gamma production) against tumor antigens [&lt;ulink linkID="968593" linkType="Reference"&gt;968593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were published showing that the drug influenced cellular redox balance in cell and animal models [&lt;ulink linkID="896912" linkType="Reference"&gt;896912&lt;/ulink&gt;], [&lt;ulink linkID="896991" linkType="Reference"&gt;896991&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, preliminary data from mice models of acute radiation injury had shown NOV-002 to increase survival and reduce morbidity compared with placebo [&lt;ulink linkID="797140" linkType="Reference"&gt;797140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Russian preclinical studies reported in November 2005 showed that the drug increased 30-day survival in mice and rats exposed to lethal doses of radiation 2- to 3-fold [&lt;ulink linkID="633267" linkType="Reference"&gt;633267&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2009, Mundipharma International  entered an exclusive collaboration agreement with Novelos Therapeutics for the commercialization  in Europe and Asia / Pacific (excluding China) of Novelos' NOV-002. Mundipharma would also have responsibility for certain  development activities and regulatory submissions. Novelos would retain all rights and responsibilities in the Americas.   Novelos also closed a private placement with Mundipharma's associate company, &lt;ulink linkID="24191" linkType="Company"&gt;Purdue Pharma&lt;/ulink&gt;,  resulting in $10 million in gross proceeds [&lt;ulink linkID="983528" linkType="Reference"&gt;983528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, Novelos announced that the USPTO had issued US-7371411, which was equivalent to US-06312734, which covered compositions and use of NOV-002 [&lt;ulink linkID="921261" linkType="Reference"&gt;921261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, &lt;ulink linkID="27692" linkType="Company"&gt;Novelos&lt;/ulink&gt; signed an agreement with &lt;ulink linkID="1023179" linkType="Company"&gt;Lee's Pharmaceutical&lt;/ulink&gt; to develop and commercialize NOV-002 and NOV-205 for cancer and hepatitis, respectively, in China, including Hong Kong, Macau and Taiwan [&lt;ulink linkID="861719" linkType="Reference"&gt;861719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, Novelos and the Medical University of South Carolina received a $0.15 million grant from the NIH to develop the drug [&lt;ulink linkID="835271" linkType="Reference"&gt;835271&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, Novelos and the Shriners Hospitals for Children were to collaborate to assess NOV-002 for acute radiation injury. Novelos planned to submit proposals to the Department of Health and Human Services (DHHS) in 2006 to treat patients exposed to lethal radiation. The collaboration aimed to confirming and extend positive Russian preclinical finding, as well as to identify the cellular and molecular actions of NOV-002 [&lt;ulink linkID="633267" linkType="Reference"&gt;633267&lt;/ulink&gt;]. In February 2006, Novelos submitted the proposal to the DHHS. Government contracts were expected to be awarded later that year [&lt;ulink linkID="651766" linkType="Reference"&gt;651766&lt;/ulink&gt;]. In June 2006, the DHHS accepted Novelos's proposal. Awards under this program were to be made in September 2006 and would include up to 100,000 treatment courses with a further 100,000-dose order to be made at a later date [&lt;ulink linkID="675680" linkType="Reference"&gt;675680&lt;/ulink&gt;]. However, in October 2006, the DHHS determined that NOV-002 was no longer eligible for procurement under the program [&lt;ulink linkID="734278" linkType="Reference"&gt;734278&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, Novelos enlisted the&lt;ulink linkID="20675" linkType="Company"&gt; Medical University of South Carolina&lt;/ulink&gt;  to further characterize the cellular and molecular actions of NOV-002 [&lt;ulink linkID="622836" linkType="Reference"&gt;622836&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In its oxidized form, excess amounts of NOV-002 are able to exert direct and indirect antitumor effects, protect normal cells against the effects of toxic agents, promote hematopoiesis and stimulate the immune system. The proprietary formulation of NOV-002 stabilizes the peptide in its oxidized form, which is required for therapeutic action. Novelos's technology permits the large-scale production of NOV-002 [&lt;ulink linkID="363605" linkType="reference"&gt;363605&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, Phytera obtained exclusive North American rights to NOV-002 in the US. The alliance provided Novelos with a North American commercialization partner [&lt;ulink linkID="378896" linkType="reference"&gt;378896&lt;/ulink&gt;]; however, as the company appeared to have gone out of business, its involvement in this program was assumed to have been discontinued.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1015614">Pharma Vam</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>2000-04-20T00:00:00.000Z</StatusDate><Source id="363605" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="CI">Ivory Coast</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="2071133" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2010-03-18T00:00:00.000Z</StatusDate><Source id="1083115" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23066">Phytera Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2008-09-09T00:00:00.000Z</StatusDate><Source id="378896" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate>2007-02-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2006-12-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023179">Lee's Pharmaceutical Holdings Limited</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-06-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-08-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-08-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2006-07-18T00:00:00.000Z</StatusDate><Source id="678919" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate>2005-06-16T00:00:00.000Z</StatusDate><Source id="607922" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2000-03-31T00:00:00.000Z</StatusDate><Source id="363605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="CI">Ivory Coast</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2000-03-31T00:00:00.000Z</StatusDate><Source id="363605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate>2005-11-08T00:00:00.000Z</StatusDate><Source id="633267" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-04-13T00:00:00.000Z</StatusDate><Source id="783763" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023179">Lee's Pharmaceutical Holdings Limited</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-12-17T00:00:00.000Z</StatusDate><Source id="861719" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-02-11T00:00:00.000Z</StatusDate><Source id="983528" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-02-11T00:00:00.000Z</StatusDate><Source id="983528" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2005-06-16T00:00:00.000Z</StatusDate><Source id="607922" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2000-04-20T00:00:00.000Z</StatusDate><Source id="363605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23066">Phytera Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2000-08-15T00:00:00.000Z</StatusDate><Source id="378896" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate>2005-08-10T00:00:00.000Z</StatusDate><Source id="617143" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2005-06-16T00:00:00.000Z</StatusDate><Source id="607922" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27692">Cellectar Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2006-06-29T00:00:00.000Z</StatusDate><Source id="683756" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="27692">Cellectar Biosciences Inc</OwnerCompany><Country id="US">US</Country><Indication id="1262">Non-small-cell lung cancer</Indication><AwardedIndication>Treatment of non-small-cell lung cancer (NSCLC)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-08-07T00:00:00.000Z</MileStoneDate><Source id="682452" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1023179">Lee's Pharmaceutical Holdings Limited</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045514">Mundipharma International Corp Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="20675">Medical University of South Carolina</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21061">Shriners Hospitals for Children</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23066">Phytera Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24191">Purdue Pharma LP</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27692">Cellectar Biosciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>10</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>3</CountActive><CountInactive>1</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>1</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>N.N.Cl[Pt]Cl</Smiles><Smiles>C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)[O-])NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)[O-])[C@@H](C(=O)O)N.N.N.[Na+].[Na+].Cl[Pt]Cl</Smiles><Smiles>C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N.[Na+].[Na+]</Smiles><Smiles>C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N</Smiles></StructureSmiles><Deals><Deal id="111093" title="Lee's to develop NOV-002 and NOV-205 in China, Hong Kong, Macau and Taiwan"/><Deal id="116614" title="Phytera to develop and commercialize Novelos Therapeutics' BAM-002 and related compunds in North America"/><Deal id="120638" title="Purdue Pharma and Novelos to enter agreement related to Mundipharma's acquisition of NOV-002 rights"/><Deal id="120639" title="Mundipharma International to acquire rights to Novelos' NOV-002 in Europe and certain Asia/ Pacific territories   "/><Deal id="120650" title="Medical University of South Carolina to evaluate Novelos' NOV-002 and NOV-205   "/><Deal id="125296" title="NIH to award Medical University of South Carolina grant to develop NOV-002"/><Deal id="125297" title="National Cancer Institute to award Novelos grant to develop NOV-002 against cancer "/><Deal id="125298" title="Novelos and Shriners Hospitals to assess NOV-002 for radiation injury"/><Deal id="125299" title="DHHS to award Novelos funding to support NOV-002 development for radiation exposure"/><Deal id="128181" title="NIH to award funding to Novelos for development of NOV-002 and NOV-205 for radiation-induced pulmonary injury"/><Deal id="128182" title="Massachusetts General Hospital to collaborate on the study of Novelos' NOV-002 and NOV-205 for radiation-induced pulmonary injury"/></Deals><PatentFamilies><PatentFamily id="1609379" number="WO-00031120" title="Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis"/><PatentFamily id="2200731" number="US-20110064828" title="Treatment of metastatic tumors and other conditions"/><PatentFamily id="635345" number="UA-00013176" title="Method for treating psoriasis"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lee's Pharmaceutical Holdings Limited" id="1023179"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mundipharma International Corp Ltd" id="1045514"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kharkiv National Medical University" id="1068191"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical University of South Carolina" id="20675"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wistar Institute of Anatomy &amp; Biology" id="20944"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cellectar Biosciences Inc" id="27692"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ZAO &quot;VAM&quot;" id="27833"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>